Merck Cozaar, Bristol Avapro Gain Nephropathy Indication On Shared Data
Executive Summary
FDA approvals of Merck's Cozaar (losartan) and Bristol/Sanofi's Avapro (irbesartan) for the treatment of nephropathy in type 2 diabetes patients are based on data shared by the companies under a reciprocal agreement
You may also be interested in...
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
GSK Coreg Post-MI Survival Backed By Beta Blocker Experience – FDA Cmte.
GlaxoSmithKline's Coreg use in the reduction of post-myocardial infarction mortality is supported by previous experience with other beta blockers in that setting, FDA's cardiovascular advisory committee said